Picking the right measurements to assess improvement in medication management depends largely on the what group is being considered, said Woody Eisenberg, MD, senior vice president of performance measurement and strategic alliances for the Pharmacy Quality Alliance.
senior vice president of performance measurement and strategic alliances for the Pharmacy Quality Alliance (PQA).
Picking the right measurements to assess improvement in medication management depends largely on the what group is being considered, said Woody Eisenberg, MD,
The Medicaid population has different needs from the Medicare population as well as the commercially insured population.
He went on to discuss that while PQA does not currently take affordability into its measurement processes yet, it is looking into it.
"As we're moving forward, I know that one of our measurement teams or another will be focused on this topic," Dr Eisenberg said.
A meta-analysis showed that control group outcomes in psilocybin trials for depression were significantly weaker than those in selective serotonin reuptake inhibitor (SSRI) and esketamine trials, suggesting that psilocybin’s large observed treatment effects may be inflated by methodological factors such as functional unblinding and expectancy bias.
Read More
It Take a Village in Cancer Care: A Q&A With David Nguyen, MD
July 23rd 2025David Nguyen, MD, medical oncologist with Tufts Medicine and Lowell General Hospital, discusses the evolving landscape of advanced cancer treatments like chimeric antigen receptor T-cell therapy and bispecific antibodies
Read More